Top

Reviews in Endocrine and Metabolic Disorders

Published in:

01-03-2015

The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity

Authors: Ningwen Tai, F. Susan Wong, Li Wen

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 1/2015

Abstract

Diabetes is a group of metabolic disorders characterized by persistent hyperglycemia and has become a major public health concern. Autoimmune type 1 diabetes (T1D) and insulin resistant type 2 diabetes (T2D) are the two main types. A combination of genetic and environmental factors contributes to the development of these diseases. Gut microbiota have emerged recently as an essential player in the development of T1D, T2D and obesity. Altered gut microbiota have been strongly linked to disease in both rodent models and humans. Both classic 16S rRNA sequencing and shot-gun metagenomic pyrosequencing analysis have been successfully applied to explore the gut microbiota composition and functionality. This review focuses on the association between gut microbiota and diabetes and discusses the potential mechanisms by which gut microbiota regulate disease development in T1D, T2D and obesity.

Kamada N et al. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol. 2013;13(5):321–35.CrossRefPubMed

Geuking MB, et al. The interplay between the gut microbiota and the immune system. Gut Microbes. 2014;5(3).

Vieira SM, Pagovich OE, Kriegel MA. Diet, microbiota and autoimmune diseases. Lupus. 2014;23(6):518–26.CrossRefPubMed

Nielsen DS, et al. Beyond genetics. Influence of dietary factors and gut microbiota on type 1 diabetes. FEBS Lett. 2014.

Vaarala O. Human intestinal microbiota and type 1 diabetes. Curr Diabetes Rep. 2013;13(5):601–7.CrossRef

Wen L et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature. 2008;455(7216):1109–13.CrossRefPubMedCentralPubMed

Alkanani AK et al. Induction of diabetes in the RIP-B7.1 mouse model is critically dependent on TLR3 and MyD88 pathways and is associated with alterations in the intestinal microbiome. Diabetes. 2014;63(2):619–31.CrossRefPubMed

Roesch LF et al. Culture-independent identification of gut bacteria correlated with the onset of diabetes in a rat model. ISME J. 2009;3(5):536–48.CrossRefPubMedCentralPubMed

Hara N et al. Prevention of virus-induced type 1 diabetes with antibiotic therapy. J Immunol. 2012;189(8):3805–14.CrossRefPubMed

10.

Peng J, et al. Long term effect of gut microbiota transfer on diabetes development. J Autoimmun. 2014.

11.

Dahlquist G, Kallen B. Maternal-child blood group incompatibility and other perinatal events increase the risk for early-onset type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1992;35(7):671–5.CrossRefPubMed

12.

Knip M, Simell O. Environmental triggers of type 1 diabetes. Cold Spring Harb Perspect Med. 2012;2(7):a007690.CrossRefPubMedCentralPubMed

13.

Rosenbauer J, Herzig P, Giani G. Early infant feeding and risk of type 1 diabetes mellitus-a nationwide population-based case–control study in pre-school children. Diabetes Metab Res Rev. 2008;24(3):211–22.CrossRefPubMed

14.

Funda DP et al. Gluten-free diet prevents diabetes in NOD mice. Diabetes Metab Res Rev. 1999;15(5):323–7.CrossRefPubMed

15.

Lefebvre DE et al. Dietary proteins as environmental modifiers of type 1 diabetes mellitus. Annu Rev Nutr. 2006;26:175–202.CrossRefPubMed

16.

Schmid S et al. Delayed exposure to wheat and barley proteins reduces diabetes incidence in non-obese diabetic mice. Clin Immunol. 2004;111(1):108–18.CrossRefPubMed

17.

Marietta EV et al. Low incidence of spontaneous type 1 diabetes in non-obese diabetic mice raised on gluten-free diets is associated with changes in the intestinal microbiome. PLoS One. 2013;8(11):e78687.CrossRefPubMedCentralPubMed

18.

Hansen CH et al. A maternal gluten-free diet reduces inflammation and diabetes incidence in the offspring of NOD mice. Diabetes. 2014;63(8):2821–32.CrossRefPubMed

19.

Ejsing-Duun M et al. Dietary gluten reduces the number of intestinal regulatory T cells in mice. Scand J Immunol. 2008;67(6):553–9.CrossRefPubMed

20.

Adlercreutz EH et al. A gluten-free diet lowers NKG2D and ligand expression in BALB/c and non-obese diabetic (NOD) mice. Clin Exp Immunol. 2014;177(2):391–403.CrossRefPubMedCentralPubMed

21.

Larsen J, et al. Dietary gluten increases natural killer cell cytotoxicity and cytokine secretion. Eur J Immunol. 2014.

22.

Gur C et al. The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat Immunol. 2010;11(2):121–8.CrossRefPubMed

23.

Poirot L, Benoist C, Mathis D. Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity. Proc Natl Acad Sci U S A. 2004;101(21):8102–7.CrossRefPubMedCentralPubMed

24.

Scaramuzza AE et al. Type 1 diabetes and celiac disease: the effects of gluten free diet on metabolic control. World J Diabetes. 2013;4(4):130–4.CrossRefPubMedCentralPubMed

25.

Abid N et al. Clinical and metabolic effects of gluten free diet in children with type 1 diabetes and coeliac disease. Pediatr Diabetes. 2011;12(4 Pt 1):322–5.CrossRefPubMed

26.

Antvorskov JC et al. Dietary gluten and the development of type 1 diabetes. Diabetologia. 2014;57(9):1770–80.CrossRefPubMedCentralPubMed

27.

Hummel S et al. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care. 2011;34(6):1301–5.CrossRefPubMedCentralPubMed

28.

Kaukinen K et al. No effect of gluten-free diet on the metabolic control of type 1 diabetes in patients with diabetes and celiac disease. Retrospective and controlled prospective survey. Diabetes Care. 1999;22(10):1747–8.CrossRefPubMed

29.

Leeds JS et al. High prevalence of microvascular complications in adults with type 1 diabetes and newly diagnosed celiac disease. Diabetes Care. 2011;34(10):2158–63.CrossRefPubMedCentralPubMed

30.

Gray JD, Shiner M. Influence of gastric pH on gastric and jejunal flora. Gut. 1967;8(6):574–81.CrossRefPubMed

31.

Sofi MH et al. pH of drinking water influences the composition of gut microbiome and type 1 diabetes incidence. Diabetes. 2014;63(2):632–44.CrossRefPubMedCentralPubMed

32.

Wolf KJ et al. Consumption of acidic water alters the gut microbiome and decreases the risk of diabetes in NOD mice. J Histochem Cytochem. 2014;62(4):237–50.CrossRefPubMed

33.

Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 2014;35(3):347–69.CrossRefPubMed

34.

Zandman-Goddard G, Peeva E, Shoenfeld Y. Gender and autoimmunity. Autoimmun Rev. 2007;6(6):366–72.CrossRefPubMed

35.

Yurkovetskiy L et al. Gender bias in autoimmunity is influenced by microbiota. Immunity. 2013;39(2):400–12.CrossRefPubMed

36.

Markle JG et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science. 2013;339(6123):1084–8.CrossRefPubMed

37.

Gale EA, Gillespie KM. Diabetes and gender. Diabetologia. 2001;44(1):3–15.CrossRefPubMed

38.

Giongo A et al. Toward defining the autoimmune microbiome for type 1 diabetes. ISME J. 2011;5(1):82–91.CrossRefPubMedCentralPubMed

39.

Murri M et al. Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case–control study. BMC Med. 2013;11:46.CrossRefPubMedCentralPubMed

40.

Brown CT et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One. 2011;6(10):e25792.CrossRefPubMedCentralPubMed

41.

de Goffau MC et al. Fecal microbiota composition differs between children with beta-cell autoimmunity and those without. Diabetes. 2013;62(4):1238–44.CrossRefPubMedCentralPubMed

42.

Mejia-Leon ME et al. Fecal microbiota imbalance in Mexican children with type 1 diabetes. Sci Rep. 2014;4:3814.CrossRefPubMedCentralPubMed

43.

Ringel-Kulka T et al. Intestinal microbiota in healthy U.S. young children and adults--a high throughput microarray analysis. PLoS One. 2013;8(5):e64315.CrossRefPubMedCentralPubMed

44.

de Goffau MC et al. Aberrant gut microbiota composition at the onset of type 1 diabetes in young children. Diabetologia. 2014;57(8):1569–77.CrossRefPubMed

45.

Van den Abbeele P et al. Butyrate-producing clostridium cluster XIVa species specifically colonize mucins in an in vitro gut model. ISME J. 2013;7(5):949–61.CrossRefPubMedCentralPubMed

46.

Van Immerseel F et al. Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. J Med Microbiol. 2010;59(Pt 2):141–3.CrossRefPubMed

47.

Endesfelder D et al. Compromised gut microbiota networks in children with anti-islet cell autoimmunity. Diabetes. 2014;63(6):2006–14.CrossRefPubMed

48.

Kriegel MA et al. Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. Proc Natl Acad Sci U S A. 2011;108(28):11548–53.CrossRefPubMedCentralPubMed

49.

Yang Y et al. Focused specificity of intestinal TH17 cells towards commensal bacterial antigens. Nature. 2014;510(7503):152–6.CrossRefPubMedCentralPubMed

50.

Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008;453(7195):620–5.CrossRefPubMed

51.

Ochoa-Reparaz J et al. A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol. 2010;3(5):487–95.CrossRefPubMed

52.

Surana NK, Kasper DL. The yin yang of bacterial polysaccharides: lessons learned from B. fragilis PSA. Immunol Rev. 2012;245(1):13–26.CrossRefPubMedCentralPubMed

53.

Ochoa-Reparaz J et al. Central nervous system demyelinating disease protection by the human commensal Bacteroides fragilis depends on polysaccharide A expression. J Immunol. 2010;185(7):4101–8.CrossRefPubMed

54.

Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A. 2010;107(27):12204–9.CrossRefPubMedCentralPubMed

55.

Mazmanian SK et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122(1):107–18.CrossRefPubMed

56.

Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004;89(6):2595–600.CrossRefPubMed

57.

Haslam DW, James WP. Obesity. Lancet. 2005;366(9492):1197–209.CrossRefPubMed

58.

Bleich S et al. Why is the developed world obese? Annu Rev Public Health. 2008;29:273–95.CrossRefPubMed

59.

Lau DC et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ. 2007;176(8):S1–13.CrossRefPubMedCentralPubMed

60.

Musso G, Gambino R, Cassader M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med. 2011;62:361–80.CrossRefPubMed

61.

Remely M et al. Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity. Gene. 2014;537(1):85–92.CrossRefPubMed

62.

Fava F et al. The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome ‘at-risk’ population. Int J Obes (Lond). 2013;37(2):216–23.CrossRef

63.

Karlsson F et al. Assessing the human gut microbiota in metabolic diseases. Diabetes. 2013;62(10):3341–9.CrossRefPubMedCentralPubMed

64.

Kotzampassi K, Giamarellos-Bourboulis EJ, Stavrou G. Obesity as a consequence of gut bacteria and diet interactions. ISRN Obes. 2014;2014:651895.PubMedCentralPubMed

65.

Moreno-Indias I et al. Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus. Front Microbiol. 2014;5:190.CrossRefPubMedCentralPubMed

66.

Turnbaugh PJ et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480–4.CrossRefPubMedCentralPubMed

67.

Ley RE. Obesity and the human microbiome. Curr Opin Gastroenterol. 2010;26(1):5–11.CrossRefPubMed

68.

Zhao L. The gut microbiota and obesity: from correlation to causality. Nat Rev Microbiol. 2013;11(9):639–47.CrossRefPubMed

69.

Armougom F et al. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. PLoS One. 2009;4(9):e7125.CrossRefPubMedCentralPubMed

70.

Ley RE et al. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022–3.CrossRefPubMed

71.

Duncan SH et al. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes (Lond). 2008;32(11):1720–4.CrossRef

72.

Schwiertz A et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010;18(1):190–5.CrossRef

73.

Zhang C et al. Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice. ISME J. 2010;4(2):232–41.CrossRefPubMed

74.

Parks BW et al. Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice. Cell Metab. 2013;17(1):141–52.CrossRefPubMedCentralPubMed

75.

Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793–801.CrossRefPubMedCentralPubMed

76.

Tang T et al. Uncoupling of inflammation and insulin resistance by NF-kappa B in transgenic mice through elevated energy expenditure. J Biol Chem. 2010;285(7):4637–44.CrossRefPubMedCentralPubMed

77.

Lee YS et al. Inflammation is necessary for long-term but not short-term high-fat diet-induced insulin resistance. Diabetes. 2011;60(10):2474–83.CrossRefPubMedCentralPubMed

78.

Lee JY, Zhao L, Hwang DH. Modulation of pattern recognition receptor-mediated inflammation and risk of chronic diseases by dietary fatty acids. Nutr Rev. 2010;68(1):38–61.CrossRefPubMed

79.

Ye J. Mechanisms of insulin resistance in obesity. Front Med. 2013;7(1):14–24.CrossRefPubMedCentralPubMed

80.

Vijay-Kumar M et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010;328(5975):228–31.CrossRefPubMed

81.

Davis JE et al. Absence of Tlr2 protects against high-fat diet-induced inflammation and results in greater insulin-stimulated glucose transport in cultured adipocytes. J Nutr Biochem. 2011;22(2):136–41.CrossRefPubMed

82.

Ehses JA et al. Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia. 2010;53(8):1795–806.CrossRefPubMed

83.

Caricilli AM et al. Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice. PLoS Biol. 2011;9(12):e1001212.CrossRefPubMedCentralPubMed

84.

Ubeda C et al. Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR-deficient mice. J Exp Med. 2012;209(8):1445–56.CrossRefPubMedCentralPubMed

85.

Azad MB, et al., Infant antibiotic exposure and the development of childhood overweight and central adiposity. Int J Obes (Lond). 2014.

86.

Million M, Raoult D. The role of the manipulation of the gut microbiota in obesity. Curr Infect Dis Rep. 2013;15(1):25–30.CrossRefPubMed

87.

Murphy R, et al. Antibiotic treatment during infancy and increased body mass index in boys: an international cross-sectional study. Int J Obes (Lond). 2013.

88.

Million M et al. Lactobacillus reuteri and Escherichia coli in the human gut microbiota may predict weight gain associated with vancomycin treatment. Nutr Diabetes. 2013;3:e87.CrossRefPubMedCentralPubMed

89.

Murphy EF et al. Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity. Gut. 2013;62(2):220–6.CrossRefPubMed

90.

Liou AP et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013;5(178):178ra41.CrossRefPubMedCentralPubMed

91.

Ridaura VK et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341(6150):1241214.CrossRefPubMed

92.

Duca FA et al. Replication of obesity and associated signaling pathways through transfer of microbiota from obese-prone rats. Diabetes. 2014;63(5):1624–36.CrossRefPubMed

93.

Zhang H et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A. 2009;106(7):2365–70.CrossRefPubMedCentralPubMed

94.

Brunetti P. The lean patient with type 2 diabetes: characteristics and therapy challenge. Int J Clin Pract Suppl. 2007;153:3–9.

95.

Camhi SM, Katzmarzyk PT. Differences in body composition between metabolically healthy obese and metabolically abnormal obese adults. Int J Obes (Lond). 2014;38(8):1142–5.CrossRef

96.

Karelis AD. Metabolically healthy but obese individuals. Lancet. 2008;372(9646):1281–3.CrossRefPubMed

97.

Larsen N et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010;5(2):e9085.CrossRefPubMedCentralPubMed

98.

Zhang X et al. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One. 2013;8(8):e71108.CrossRefPubMedCentralPubMed

99.

Qin J et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60.CrossRefPubMed

100.

Karlsson FH et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99–103.CrossRefPubMed

Title: The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity
Authors: Ningwen Tai
F. Susan Wong
Li Wen
Publication date: 01-03-2015
Publisher: Springer US
Published in: Reviews in Endocrine and Metabolic Disorders / Issue 1/2015
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-015-9309-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Regulation of energy balance by inflammation: Common theme in physiology and pathology

The role of the Nrf2/Keap1 pathway in obesity and metabolic syndrome

Pleiotropic actions of iron balance in diabetes mellitus

Angiogenesis in diabetes and obesity

Inflammation in sleep apnea: An update

The update of anthocyanins on obesity and type 2 diabetes: Experimental evidence and clinical perspectives

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page